Dimerix Limited · ASX:DXB
Dimerix — J.P. Morgan Healthcare Conference 2026
27 slides from Dimerix's conference presentation, Jan 15, 2026
Slide 1: Investor Presentation
Developing new therapies to treat inflammatory causes of kidney disease with unmet clinical needs Investor Presentation J.P. Morgan Healthcare Conference 12-15 January 2026 San Francisco, California Authorised for lodgement by the Board of the Company
Slide 2: Forward looking statements
Forward looking statements This presentation includes forward-looking statements that are subject to risks and uncertainties. Although we believe that the expectations reflected in the forward looking statements are reasonable at this time, Dimerix can give no assurance that these expectations will
Slide 3: Overview: Phase 3 Global Opportunity
Overview Phase 3 Global Opportunity Phase 3 trial FSGS indication No approved Orphan drug 4 commercial up to $1.4 billion >$65 million recruitment is a rare disease treatments designations partners in total complete in that causes scarring specifically for regulatory, DMX-200 licensed development an
Slide 4: Corporate overview
Corporate overview S H A R E P R I C E Ticker Symbol ASX: DXB Cash Balance (Sep25) $49.2 million Market Capitalisation1 $330 million Share price1 $0.55 Total ordinary shares on issue1 600,396,776 Average Daily Liquidity by value for $1.2 million past 30 trading days2 S UBSTA N T IA L S H A R E H O L
Slide 5: Cycle of damage in glomerular diseases
Cycle of damage : in glomerular diseases Existing blood pressure medication What is FSGS? Glomeruli exposed to stress from high blood pressure DMX-200 Focal = some 1 Segmental = sections High blood pressure causes hyperfiltration within filter units Glomerulo = of the kidney filtering units (glomeru
Slide 6: Measuring kidney damage – surrogate endpoints
Measuring kidney damage – surrogate endpoints 1. Proteinuria 2. Estimated glomerular filtration rate (eGFR) Treatments, such as DMX-200, aim to • A healthy kidney is a good filter and allows little to no protein bring the FSGS slope back up: into the urine2 • can add years to the life of the kidney
Slide 7: DMX-200: unique pharmacology
DMX-200: unique pharmacology MCP-1 & Angiotensin II present 50% uMCR normalised Complex of CCR2 and Unlike other CCR2 antagonists in-human 0% in-vitro AT1R increases aberrant investigated to date, treatment Only MCP-1 present signaling when both with DMX-200 reduces the urine -37%* -39%* Angiotensin
Slide 8: DMX-200: Phase 2 met primary and secondary endpoints
DMX-200: Phase 2 met primary and secondary endpoints Clinically meaningful outcomes achieved for patients,2,3 with no safety concerns Average reduction of 17% in proteinuria after 16 weeks treatment on DMX-200 versus placebo1 “Any reduction in proteinuria could yield years of preserved native kidney
Slide 9: Phase 3 clinical trial
European Renal Association Posters 2025 phase 3 clinical trial A randomised, double-blind, multi-centre, placebo-controlled study of renal outcomes of DMX-200 in patients with FSGS receiving an ARB (n=≥286) Background Phase 3 Trial Timeline Open Label Extension Successful interim analysis1 Planned b
Slide 10: Adult patient recruitment by territory
Adult patient recruitment by territory Trial designed for potential Recruitment approval globally completed (adult population) 309 Adult patients recruited, randomised and dosed (target ≥286)1 5 Paediatric patients recruited, randomised and dosed1 Latin America Asia Pacific US / Europe 1. As at 09 J
Slide 11: Blinded analysis process
Blinded analysis process PARASOL working group conducted “ACTION3-like” population analysis of larger PARASOL observation dataset1,2 • Results of this analysis are generally consistent with the broader PARASOL analysis conducted in 2024 • Potential relationship between proteinuria at 12 months and s
Slide 12: Competitive landscape in FSGS
Competitive landscape in FSGS Low competition in inflammatory treatment options, huge unmet medical need DMX-200 is the only inflammatory modulator in development Phase 1 Phase 2 Phase 3 Company DMX-200 Inflammatory modulator Sparsentan AT1R/ETAR dual antagonist – Failed Phase 3 eGFR endpoint: resub
Slide 13: Rare kidney disease – a potential growth market
Rare kidney disease – a potential growth market Biopsy 7 per 1,000,000 FSGS is the most DMX-200 frequent primary FSGS diagnosis driven by glomerular disease Commercial rates of biopsy - growth Global incidence rate of that reaches end-stage manufacturing sites potential as biopsy rates FSGS per capi
Slide 14: Summary of licensing deals for DMX-200 to date
Summary of licensing deals for DMX-200 to date Licensing deals collectively Dimerix has successfully partnered DMX-200 across key markets valued up to 1 2 3 4 ~AU$1.4 billion in total upfront and potential milestone fees plus royalties1 United States EU, CA, AU, NZ GCC, Iraq Japan AU$48 AU$10.8 AU$0
Slide 15: Intellectual property portfolio
Intellectual property portfolio DMX-200 Exclusivity Portfolio 3 7/10 years Exp.2042 Orphan exclusivity from (if granted) marketing approval date in many territories1 Portfolio 2 Formulation Portfolio 5 Global application3 + Exp.2042 Exp.2045/6 (if granted) Paediatric (if granted) exclusivity period
Slide 16: Growth strategy
Growth strategy Deliver ACTION3 Phase 3 Expand global commercial Advance pipeline development clinical trial partnerships • Identify and progress new assets in • Ensure drug supply continuity and • Build on existing licensing agreements renal and/or rare disease indications patient visits for recrui
Slide 17: Achievements and potential catalysts
Achievements and potential catalysts 1 2 3 FY FY Potential 2024/25 2025/26 upside DMX-200 licensed in US for up to Outcome of PARASOL working group analysis received5 ➢ Additional commercial licensing ~AU$940 million1 partners for DMX-200: Dimerix continues DMX-200 licensed in Japan for up to Phase
Slide 18: Well positioned to deliver against strategic plan
(ASX:DXB) W E L L P O S I T I O N E D TO D E L I V E R AGA I N ST ST R AT EG I C P L A N ESG Statement Dimerix is committed to integrating Environmental, Social and Governance (ESG) considerations across the development cycle of its programs, processes and decision making. The Dimerix commitment to
Slide 19: Dimerix board
Dimerix board Mark Diamond Nina Webster Hugh Alsop Sonia Poli Clinton Snow BSc, MBA PhD, MBA, M.IP.Law BSc (Hons), MBA PhD BEng (Hons), BCom Non-Executive Chairman CEO & Managing Director Non-Executive Director Non-Executive Director Non-Executive Director Previous experience: Previous experience: P
Slide 20: Dimerix management
Dimerix management Nina Webster Hamish George David Fuller Robert Shepherd Bronwyn Pollock PhD, MBA, M.IP.Law Bcom, CA, GIA (Cert) B. Pharm (Hons), MBBS PhD, MBA, BSc (Hons), MBA CEO & Managing Director CFO & Company Secretary CMO COO VP, Product Development Previous experience: Previous experience:
Slide 21: Medical Advisory Board
Medical Advisory Board Professor Professor Professor Associate Professor Dr Muh Geot Wong Professor Associate Professor Hiddo Heerspink Alessia Fornoni Jonathan Barratt Lesley Inker Howard Trachtman Laura Mariani PhD MD, PhD, FASN MD, PhD, FRCP MD, MS, FRCPC MBBS, PhD, FRCP MD, FASN MD, MSCE Profess
Slide 22: Renal disease landscape
Renal disease landscape “A squeaky wheel waiting for grease: 50 years of kidney disease management in the US”1 Historical lack of incentives 2018: workshops and 2019 changes in US federal Public health policy, and public policy have regulatory acceptance of policy and rapid adoption of legislation a
Slide 23: Clinical study change: use of surrogate endpoints
Clinical study change: use of surrogate endpoints A surrogate endpoint is an intermediate outcome which substitutes the hard endpoint for a disease (e.g. kidney failure), FDA led working Dimerix starts group, called which can take much longer to achieve recruiting patients PARASOL, initiated for glo
Slide 24: Kidney disease is high interest area for pharma
Kidney disease is high interest area for pharma Prevalence of Kidney Failure, 2001-20232 Kidney disease is the third-fastest-growing cause of death globally1 • In the US alone, the number of people with kidney failure increased by >200% from 2001 to 20232 Number of patients • By 2040, it is expected
Slide 25: DMX-200 – working on inflammatory signalling pathway
DMX-200 – working on inflammatory signalling pathway A CCR2 inhibitor working synergistically alongside the current standard of care (AT1R blocker): G protein-coupled receptor (GPCR) New Chemical Entity status, 2 x 120mg capsule daily Consistently safe and well 4 clinical studies completed with orph
Slide 26: DMX-200 unique heteromer pharmacology
DMX-200 unique heteromer pharmacology Macrophage infiltration Proprietary discovery platform (Receptor-HIT) identified: • Formation of AT1R and CCR2 heteromers; • Novel pharmacology (potentiation of signaling) Proteinuria • Dual antagonism required for completed inhibition Retained podocyte numb
Slide 27: DMX-200 Phase 2 effect on inflammatory biomarker
DMX-200 Phase 2 effect on inflammatory biomarker1 Average baseline MCP-1 versus Change in MCP-1 over time on uMCR normalised to baseline v time average baseline proteinuria DMX-200 versus placebo N=7, GeoMean 50% 1.5 uMCR normalised 0% 1.0 -37%* -39%* -50% 0.5 MCP-1 levels reduced high MCP-1 correla